Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial

BACKGROUND: More than 60% of oligo-recurrent prostate cancer (PCa) patients treated with metastasis-directed radiotherapy (MDRT) develop biochemical recurrence within 2 years. This recurrence rate emphasises the need for improved treatment and patient selection. In line with the treatment of primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, J., Staal, F. H. E., Brouwer, C. L., Langendijk, J. A., de Jong, I. J., van Moorselaar, R. J. A., Schuit, E., Verzijlbergen, J. F., Smeenk, R. J., Aluwini, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063099/
https://www.ncbi.nlm.nih.gov/pubmed/35501744
http://dx.doi.org/10.1186/s12885-022-09523-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063099/
https://www.ncbi.nlm.nih.gov/pubmed/35501744
http://dx.doi.org/10.1186/s12885-022-09523-2

Ejemplares similares